Download PDF
Zeitschrift für Palliativmedizin 2009; 10(3): 141-153
DOI: 10.1055/s-0029-1220392
CME-Fortbildung

© Georg Thieme Verlag KG Stuttgart · New York

Maligner Aszites

Pathogenese, Diagnose und Möglichkeiten der SymptomkontrolleMalignant AscitesPathogenesis, Diagnosis and Possibilities of Symptom ManagementG.  Becker, K.  Jaroslawski, F.  Momm, P.  Deibert
Further Information

Publication History

Publication Date:
24 August 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Maligner Aszites ist definiert als abnorme Ansammlung größerer Flüssigkeitsmengen in der Bauchhöhle als Folge einer Tumorerkrankung. Große Mengen von Aszites führen nicht nur zu einem beeinträchtigten Körperbild und reduzierter Mobilität, sondern durch den erhöhten abdominellen Druck auch zu belastenden Symptomen wie Schmerzen, Atemnot, Appetitverlust und Übelkeit. Ziel der palliativmedizinischen Betreuung ist hier, eine gute Symptomlinderung mit relativ unbelastenden und die verbleibende Lebensqualität möglichst nicht weiter einschränkenden Behandlungsmaßnahmen zu erreichen. Im Folgenden soll daher ein kurzer Überblick zur Pathophysiologie, Diagnose und Therapie des malignen Aszites gegeben werden.

Abstract

Malignant ascites occurs in association with a variety of neoplasms and is defined as abnormal accumulation of fluid in the peritoneal cavity as a consequence of cancer. Although paracentesis, diuretics and shunting are commonly used procedures, the evidence is weak. This article provides an overview of pathogenesis, diagnosis and therapy of malignant ascites. Based on a review of the literature a guideline on the management of symptomatic malignant ascites by abdominal paracentesis, diuretics and shunting will be presented.

Literatur

  • 1 Atkinson M. Ascites in liver disease.  Postgrad Med J. 1956;  32 482-485
    CrossrefPubMedGoogle Scholar
  • 2 D'Amico G, Morabito A, Pagliaro L. et al . Survival and prognostic indicators in compensated and decompensated cirrhosis.  Dig Dis Sci. 1986;  31 468-475
    CrossrefPubMedGoogle Scholar
  • 3 Regnard C F, Mannix K. Management of ascites in advanced cancer – a flow diagram.  Palliative Medicine. 1989;  4 45-47
    PubMedGoogle Scholar
  • 4 Radbruch L, Ostgathe C, Elsner F. et al . Prozesse und Interventionen auf den deutschen Palliativstationen. Ergebnisse der Kerndokumentation 2001.  Schmerz. 2004;  18 179-188
    PubMedGoogle Scholar
  • 5 Ringenberg Q S, Doll D C, Loy T S. et al . Malignant ascites of unknown origin.  Cancer. 1989;  64 753-755
    CrossrefPubMedGoogle Scholar
  • 6 Wiest R, Schölmerich J. Aktuelle Diagnostik und Therapie des Ascites.  Gastroenterologe. 2008;  1 57-67
    PubMedGoogle Scholar
  • 7 Smith E M, Jayson G C. The current and future management of malignant ascites.  Clin Oncol (R Coll Radiol). 2003;  15 59-72
    CrossrefPubMedGoogle Scholar
  • 8 Adam R A, Adam Y G. Malignant ascites: past, present, and future.  J Am Coll Surg. 2004;  198 999-1011
    CrossrefPubMedGoogle Scholar
  • 9 Runyon B A. Care of patients with ascites.  N Engl J Med. 1994;  330 337-342
    CrossrefPubMedGoogle Scholar
  • 10 Wiest R, Schölmerich J. Diagnostik und Therapie des Aszites.  Dtsch Ärztebl. 2006;  103 A1972-A1981
    PubMedGoogle Scholar
  • 11 Bergmann J F, Bidart J M, George M. et al . Elevation of CA 125 in patients with benign and malignant ascites.  Cancer. 1987;  59 213-217
    CrossrefPubMedGoogle Scholar
  • 12 Rimola A, Garcia-Tsao G, Navasa M. et al . Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club.  J Hepatol. 2000;  32 142-153
    PubMedGoogle Scholar
  • 13 Wong F, Bernardi M, Balk R. et al . Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club.  Gut. 2005;  54 718-725
    CrossrefPubMedGoogle Scholar
  • 14 Appenrodt B, Sauerbruch T. Antibiotische Therapie und Prophylaxe bei Leberzirrhose und Infektion.  Dtsch Med Wochenschr. 2007;  132 623-626
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Becker G, Galandi D, Blum H E. Malignant ascites: systematic review and guideline for treatment.  Eur J Cancer. 2006;  42 589-597
    CrossrefPubMedGoogle Scholar
  • 16 McNamara P. Paracentesis – an effective method of symptom control in the palliative care setting?.  Palliat Med. 2000;  14 62-64
    CrossrefPubMedGoogle Scholar
  • 17 Gotlieb W H, Feldman B, Feldman-Moran O. et al . Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.  Gynecol Oncol. 1998;  71 381-385
    CrossrefPubMedGoogle Scholar
  • 18 Appelqvist P, Silvo J, Salmela L. et al . On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?.  J Surg Oncol. 1982;  20 238-242
    CrossrefPubMedGoogle Scholar
  • 19 Fischer D S. Abdominal paracentesis for malignant ascites.  Arch Intern Med. 1979;  139 235
    CrossrefPubMedGoogle Scholar
  • 20 Er F, Erdmann E, Pfister R. Die Aszitespunktion.  Dtsch Med Wochenschr. 2007;  132 1177-1179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Moore K P, Aithal G P. Guidelines on the management of ascites in cirrhosis.  Gut. 2006;  55 (Suppl. 6) VI1-12
    CrossrefPubMedGoogle Scholar
  • 22 Lee C W, Bociek G, Faught W. A survey of practice in management of malignant ascites.  J Pain Symptom Manage. 1998;  16 96-101
    CrossrefPubMedGoogle Scholar
  • 23 Boyer T D. Transjugular intrahepatic portosystemic shunt: current status.  Gastroenterology. 2003;  124 1700-1710
    CrossrefPubMedGoogle Scholar
  • 24 Leveen H H, Christoudias G, Ip M. et al . Peritoneo-venous shunting for ascites.  Ann Surg. 1974;  180 580-591
    CrossrefPubMedGoogle Scholar
  • 25 Lund R, Newkirk J. Peritoneovenous shunting system for surgical management of ascites.  Contemp Surg. 1979;  14 31-45
    PubMedGoogle Scholar
  • 26 Parsons S L, Watson S A, Steele R J. Malignant ascites.  Br J Surg. 1996;  83 6-14
    CrossrefPubMedGoogle Scholar
  • 27 Barnett T D, Rubins J. Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites: a simplified percutaneous approach.  J Vasc Interv Radiol. 2002;  13 379-383
    CrossrefPubMedGoogle Scholar
  • 28 Iyengar T D, Herzog T J. Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter.  Am J Hosp Palliat Care. 2002;  19 35-38
    CrossrefPubMedGoogle Scholar
  • 29 Fleming N D, Alvarez-Secord A, Gruenigen V von. et al . Indwelling Catheters for the Management of Refractory Malignant Ascites: A Systematic Literature Overview and Retrospective Chart Review.  J Pain Symptom Manage. 2009, im Druck; 
    PubMedGoogle Scholar
  • 30 Rosenberg S, Courtney A, Nemcek A AJ. et al . Comparison of percutaneous management techniques for recurrent malignant ascites.  J Vasc Interv Radiol. 2004;  15 1129-1131
    CrossrefPubMedGoogle Scholar
  • 31 Hogberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer.  Acta Oncol. 2001;  40 340-360
    PubMedGoogle Scholar
  • 32 Alberts D S, Liu P Y, Hannigan E V. et al . Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.  N Engl J Med. 1996;  335 1950-1955
    CrossrefPubMedGoogle Scholar
  • 33 Markman M, Bundy B N, Alberts D S. et al . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gyneco.  J Clin Oncol. 2001;  19 1001-1007
    PubMedGoogle Scholar
  • 34 Baker A R, Weber J S. Treatment of malignant ascites. In: DeVita VT, Hellmann S, Rosenberg SA, eds Cancer, Principles and Practise of Oncology. Philadelphia; Lippincott 1993: 2255-2261
    Google Scholar
  • 35 Stuart G C, Nation J G, Snider D D. et al . Intraperitoneal interferon in the management of malignant ascites.  Cancer. 1993;  71 2027-2030
    CrossrefPubMedGoogle Scholar
  • 36 Rath U, Kaufmann M, Schmid H. et al . Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites.  Eur J Cancer. 1991;  27 121-125
    PubMedGoogle Scholar
  • 37 Sherer D M, Eliakim R, Abulafia O. The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female.  Gynecol Obstet Invest. 2000;  50 217-224
    CrossrefPubMedGoogle Scholar
  • 38 Xu L, Yoneda J, Herrera C. et al . Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.  Int J Oncol. 2000;  16 445-454
    PubMedGoogle Scholar
  • 39 Zucker S, Lysik R M, Zarrabi M H. et al . M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.  Cancer Res. 1993;  53 140-146
    PubMedGoogle Scholar
  • 40 Beattie G J, Smyth J F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.  Clin Cancer Res. 1998;  4 1899-1902
    PubMedGoogle Scholar
  • 41 Cairns W, Malone R. Octreotide as an agent for the relief of malignant ascites in palliative care patients.  Palliat Med. 1999;  13 429-430
    CrossrefPubMedGoogle Scholar
  • 42 Bodisch A, Muschitz C, Karthaus M. Maligner Ascites – Möglichkeiten der Symptomkontrolle.  Wien Med Wochenschr. 2008;  158 687-694
    CrossrefPubMedGoogle Scholar
  • 43 Mahler F, Rapin C H, Macgee W. Corynebacterium parvum as palliative treatment in malignant ascites.  J Palliat Care. 1988;  4 58-62
    PubMedGoogle Scholar
  • 44 Katano M, Torisu M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction.  Surgery. 1983;  93 365-373
    PubMedGoogle Scholar
  • 45 Torisu M, Katano M, Kimura Y. et al . New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.  Surgery. 1983;  93 357-364
    PubMedGoogle Scholar
  • 46 SIGN, Scottish Intercollegiate Guidelines Network .http://www.sign.ac.uk/methodology/index.html; Stand:. 09.07.2009
    Google Scholar
  • 47 Hentrich M, Hartenstein R. Behandlung maligner Körperhöhlenergüsse.  Der Onkologe. 1997;  3 163-173
    CrossrefPubMedGoogle Scholar

PD Dr. med. Dipl.-Theol. Dipl.-Caritaswiss. Gerhild Becker

MSc Palliative Care (King's College / University of London)
Palliativstation im Universitätsklinikum Freiburg

Robert-Koch-Straße 3

79106 Freiburg

Email: gerhild.becker@uniklinik-freiburg.de

      >